Biologics Business Unit

Intas’ Biologics Business Unit was launched in 2000 with a focus on developing high-quality recombinant DNA protein (rDNA) products and plasma-derived products. Its robust product portfolio consists of 13 commercialized products and a promising pipeline of 6 products. Intas’ biosimilars are registered in more than 20 countries and under registration in more than 30 countries through strategic marketing alliances. Every biological product is developed in India’s first EU approved biotech plant.

Till date, Intas’ Biologics Business Unit has reached the US $70 million in revenue with a CAGR of above 30% (FY 12-18).